The StoreGene Genetic Cardiovascular Testing Service
StoreGene's professional and confidential testing service provides physicians with a greater body of client information with which to inform their client assessments. The use of state of the art genotyping technology allows a client's DNA to be probed for genetic markers that make them more susceptible to the occurrence of a particular disease. These genetic results are then combined with conventional client data and analysed by experts in the field of cardiovascular research. The results of these analyses are reported to the physicians in a clear and detailed format facilitating their assessments.
Cardiovascular Risk Profile Test
StoreGene's unique Cardiovascular Risk Profiling service uses a purpose designed algorithm to analyse a patient's combined genetic and conventional risk factors and produce a more complete 10-year cardiovascular risk profile. The combined risk results are presented in a report that presents an individual’s estimated 10-year risk of a cardiovascular event, and shows these results in comparison with an average person of the same age, sex and ethnicity. The report explains how both the conventional and genetic factors compare to an average person, and how they combine to produce the final risk estimate. The report also includes a personalised potential therapeutic plan based on the individual’s conventional and genetic risk factors.
Familial Hypercholesterolaemia (FH) Test
Current Tests In Development
Familial hypercholesterolaemia (FH) is a genetic condition which leads to very high cholesterol levels. In the UK, about 1 in 250 people have FH. For people with FH, their high cholesterol is not caused by unhealthy diet or lifestyle, but by a mutation in one of the genes involved in clearing cholesterol from the bloodstream (LDLR, APOB and PCSK9.) Someone who has FH has a 50% chance of passing on this gene mutation to each of their children.
If people with FH are not given treatment, their high cholesterol can lead to early heart disease. Unfortunately, many people with FH have not been diagnosed. StoreGene offers next generation sequencing-based genetic testing for FH-causing mutations. StoreGene produces a personalised report highlighting any genetic mutations and associated risks. Having a genetic diagnosis for FH can aid physicians in their treatment selection for individuals with FH.
Many cardiovascular related diseases possess a genetic component. StoreGene currently has a number of risk profiling tests for cardiovascular related diseases in development that will use a combination of genotyping and conventional risk factors, to provide a more accurate assessment of disease risk.
Abdominal aortic aneurysm (AAA) is a localised swelling of the abdominal aorta. It ususally causes no symptoms, but carries a risk of rupturing, which causes massive internal bleeding and is often fatal. In addition to conventional risk factors, genetic risk factors have also been found to contribute to risk of AAA. Our test will analyse both conventional and genetic risk factors to provide an accurate individual risk estimate for the disease.
Type 2 diabetes (T2D) is a chronic condition that causes raised blood glucose levels, due to insufficient insulin production by the pancreas or a lack of sensitivity to insulin in the pancreas. People with T2D are up to five times more likely to develop cardiovascular disease, and it can also cause other serious complications like vision loss, kidney failure and lower limb amputation.
Conventional risk factors for T2D include age, ethnicity and being overweight. Genetic factors can also play a significant role with their addition to risk profiles having been shown to improve the prediction of T2D risk. Our test will analyse both conventional and genetic risk factors to provide an accurate risk estimate of an individual's likelihood of developing T2D.
Interested in offering StoreGene's services?
StoreGene liaises with prospective healthcare providers to ensure they have the required infrastructure in place to offer clients StoreGene's testing services. We provide physicians with the necessary training to accurately interpret each client's report which details their results and any associated risks. StoreGene can tailor its testing and reporting services for the needs of individual healthcare providers if required. Contact us to learn more about StoreGene and how to begin offering our services.
A. The genetic data we obtain is itself 100% accurate - by which we mean that if we do it a second time days or years later the result (number of risk gene variants an individual has) will be exactly the same. There is a degree of uncertainty about the relationship between carrying any particular gene variant and risk of CVD. The large data sets indicate that a variant on average increases risk by say 15% but with a confidence interval (range) of from 12% to 17%.
Unlike conventional factors, such as lipids or particularly blood pressure, that vary considerably for any individual from day to day and over time as we age, genetic factors do not change from day to day. Therefore the ability to estimate an individual’s “true” CVD risk from genetic factors is more stable than using conventional risk factors.